This article is more than 5 years old. Information may no longer be current.

Avedro completes 1-year follow-up in collagen cross-linking trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WALTHAM, Mass. — Avedro has completed 1-year follow-up visits in two phase 3 studies that are evaluating the safety and efficacy of corneal collagen cross-linking, according to a company press release.

The multicenter trials are looking at cross-linking for the treatment of progressive keratoconus and ectasia after refractive surgery. The procedure has already been approved for use outside of the United States, according to the release.

"Avedro's efforts to make this clinically important treatment available to U.S. patients is applauded by all U.S. ophthalmologists who today lack any approved therapeutic treatment to halt the progression of these sight-threatening conditions," Peter S. Hersh, OSN Refractive Surgery Board Member and medical monitor for the Avedro trial, said in the release.